Prothoracicotropic hormone
Prothoracicotropic hormone (PTTH) was the first insect hormone to be discovered. It was originally described simply as "brain hormone" by early workers such as Stefan Kopeć (1922) and Vincent Wigglesworth (1934), who realized that ligation of the head of immature insects could prevent molting or pupation of the body region excluded from the head if the ligation was performed before a critical age in the lifestage was reached. After a certain point the ligation had no effect and both sections of the insect would molt or pupate. However, implantation of a conspecific brain to a sessile ligated abdomen or an abdomen under diapause would induce molting or pupation. Thus, the brain was originally thought to be the source of the hormone that induces molting in insects.
Acetothiolutamide
Acetothiolutamide is a selective androgen receptor modulator (SARM) derived from the nonsteroidal antiandrogen bicalutamide that was described in 2002 and was one of the first SARMs to be discovered and developed. It is a high-affinity, selective ligand of the androgen receptor (AR) (K = 2.1–4.9 nM), where it acts as a full agonist "in vitro", and has "in vitro" potency comparable to that of testosterone. However, "in vivo", acetothiolutamide displayed overall negligible androgenic effects, though significant (albeit very low) anabolic effects were observed at high doses. In addition, notable antiandrogen effects were observed in castrated male rats treated with testosterone propionate. The discrepancy between the "in vitro" and "in vivo" actions of acetothiolutamide was determined to be related to rapid plasma clearance and extensive hepatic metabolism into a variety of metabolites with differing pharmacological activity, including AR partial agonism and antagonism. In accordance with its poor metabolic stability, acetothiolutamide is not orally bioavailable, and shows activity only via injected routes such as subcutaneous and intravenous.